Journal
JOURNAL OF VIROLOGY
Volume 79, Issue 5, Pages 2823-2830Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/JVI.79.5.2823-2830.2005
Keywords
-
Categories
Funding
- NIAID NIH HHS [U01 AI041530, AI 41530] Funding Source: Medline
- Wellcome Trust Funding Source: Medline
Ask authors/readers for more resources
Specific CD8 T-cell responses to human immunodeficiency virus type 1 (HIV-1) are induced in primary infection and make an important contribution to the control of early viral replication. The importance of neutralizing antibodies in containing primary viremia is questioned because they usually arise much later. Nevertheless antienvelope antibodies develop simultaneously with, or even before, peak viremia. We determined whether such antibodies might control viremia by complement-mediated inactivation (CMI). In each of seven patients studied, antibodies capable of CMI appeared at or shortly after the peak in viremia, concomitantly with detection of virus-specific T-cell responses. The CMI was effective on both autologous and heterologous HIV-1 isolates. Activation of the classical pathway and direct viral lysis were at least partly responsible. Since immunoglobulin G (IgG)-antibodies triggered the CMI, specific memory B cells could also be induced by vaccination. Thus, consideration should be given to vaccination strategies that induce IgG antibodies capable of CMI.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available